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Abstract 
Cytokine-based cancer immunotherapies stimulate a host’s immune system to fight 
cancer. In particular, interleukin-12 (IL-12), a potent pro-inflammatory cytokine, has 
demonstrated the ability to eliminate tumors in a number of preclinical models. Toxicities 
associated with the systemic delivery of IL-12 have precluded its use in the clinic. We are 
developing a novel chitosan-based hydrogel to maintain high local concentrations of 
cytokines, such as IL-12, in the tumor while minimizing its systemic dissemination. This 
hydrogel was found to form spontaneously within ten seconds of mixing two proprietary 
components. To increase the usefulness of the hydrogel, an efficient mixing and delivery 
system is needed. We designed and evaluated a device capable of mixing two solutions 
from two syringes during injection. A total of eight prototypes were created using three-
dimensional printers; six were printed on an Object30; one was printed on a MakerBot; 
another was printed on an uPrint SE Plus. Three tests were used to determine the 
effectiveness of the device. The first test was a dimensional test to check for fitting of the 
syringes and needle. After passing this test, the fluid dynamics were tested using distilled 
water. If the device pasted the previous tests, the third test determined the mixing ability 
of the device using the novel hydrogel. After success in all three tests, the sterility of the 
device became the main goal. Hydrogel formation was achieved but a better material for 
the device is still under investigation. 
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1. Introduction 
With the rise of cancer, investigation of cures has come to the forefront of biomedical 
sciences research. One method to fight off the disease is overstimulation of the immune 
system. Previous research demonstrated cytokine-based cancer immunotherapies are able 
to fight cancer. Interleukin-12 (IL-12) is a potent pro-inflammatory cytokine with the 
ability to eliminate tumors. IL-12 activates T lymphocytes and natural killer (NK) cells to 
cause recession of the tumors. A byproduct of the immune stimulation is the production 
of interferon (IFN)-γ. This byproduct increases the toxicity of IL-12 treatments. Phase I 
and II clinical trials determined a need for safer dosages calling for a wider therapeutic 
range. For example, the treatment for renal carcinoma using 500 ng/kg/day of rhIL-12 
caused two deaths. Toxicities associated with the systemic delivery of IL-12 cause grade 
3 and 4 adverse events. These events have precluded its use in the clinic.1, 2 
Hydrogels are hydrophilic, cross linked single chain polymers or co-polymers; the cross 
linking causes them to be insoluble in water but allows them to intake 10-20 times their 
molecular weight while retaining their three dimensional structure. The aqueous uptake 
causes the hydrogel to mimic tissue physiology increasing patient compliance. The 
integrity of the structure enables the protection of encapsulated drugs such as proteins 
and peptides. Hydrogels often display biocompatible capabilities with minimal 
immunogenicity for synthetic hydrogels. The biocompatibility and physical similarities 
cause hydrogels to be considered the closest synthetic biomaterial replica of human 
tissue. These properties make hydrogels applicable in many biomedical fields including 
drug delivery. 3, 4, 5 
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Hydrogel drug delivery is favorable because it allows time controlled drug release and 
targeted delivery. The porosity of a hydrogel dictates the rate of drug release through 
either diffusion or convection. Porosity can be controlled through the cross-link ratio of 
polymers. A greater ratio decreases the porosity causing a lengthier drug release. Its 
adhesive property allows the hydrogel to anchor in one place. With the hydrogel in one 
location, the release of the drug is targeted toward local tissue. Some hydrogels are 
deformable allowing injection but most need surgical implantation. For ease of use, 
noninvasive hydrogels are desirable.2, 3, 4 
There are two different mechanisms for hydrogel formation: physical and chemical. 
Physical hydrogel formation is caused by molecular entanglement; a polyelectrolyte 
interacts with a multivalent ion of opposite charge to cause the cross-link network. 
Because entanglement is the main mechanism, these hydrogels are reversible. Chemical 
hydrogel formation creates cross-linked networks through covalent bonds. These bonds 
are irreversible causing permanent hydrogel formation. Both hydrogels are heterogeneous 
in regard to the non-uniform density of cross-links throughout the hydrogel.6 
Chitosan, a natural derivative of chitin (shrimp exoskeleton), is biocompatible, 
biodegradable, and mucoadhesive.  This biomolecule has shown to increase bioactivity 
and local retention of cytokines such as IL-12. Along with increased potency of the 
cytokine, the chitosan/IL-12 mixture is capable of generating immunological memory to 
control metastasis and prevent tumor reoccurrence.2, 7 
A novel chitosan-based hydrogel was developed to maintain high local concentrations of 
cytokines, such as IL-12, in the tumor while minimizing its systemic dissemination. This 
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hydrogel was found to form spontaneously within ten seconds of mixing two proprietary 
components. To increase the usefulness of the hydrogel, an efficient mixing and delivery 
system is needed. In this project, a device capable of mixing two solutions from two 
syringes during injection was designed and evaluated.7 
2. Methods and Materials 
2.1 Materials. The 3mL BD Luer-Lok tip disposable syringe (BD 309657) was 
purchased from Fisher Scientific (Pittsburgh, PA). A 20-gage BD needle (BD 305179) 
was purchased from Fisher Scientific (Pittsburgh, PA). An 18-gage BD needle (BD 
305199) was purchased from Fisher Scientific (Pittsburgh, PA). The proprietary hydrogel 
was created in the Laboratory of Vaccine and Immunotherapy Delivery (Fayetteville, 
AR). 
2.2 Three Dimensional Printers. Three printers were used to create prototypes. The first 
prototypes were printed on an Object30 printer using VeroWhite, a material similar to 
polypropylene (PP) created by Stratasys. Once the dimensions were correct, the 
prototypes were printed with two other materials, polylactide (PLA) and acrylonitrile 
butadiene styrene (ABS). The MakerBot printer was used to print the PLA prototype; the 
uPrint SE Plus printed the ABS prototype. 
2.3 Creation of Prototypes. The computer aided design (CAD) software, SolidWorks, 
was used to create the prototypes. The prototypes consist of two male luer locks allowing 
two 3mL syringes to attach to the top of the device. Channels from the 3mL syringes 
allowed the two solutions to mix. The newly mixed solution exits from a needle. The 
device has a female connector at the bottom where an 18- or 20-gage needle is able to 
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attach. Once the design was printed, the prototype was evaluated for fit by connecting the 
syringes and needle while the fluid dynamics of the device were tested using distilled 
water. If the water flowed from both syringes through the device and out of the needle 
consistantly, an instant forming chitosan-based hydrogel, with a proprietary formulation, 
was used to test the mixing efficiency of the device.  
3. Results 
3.1 Fitting the Syringes and Needle. 
3.1.1 Prototype One. After printing, the fit of the syringes and needle was tested. The 
first prototype was 85.52mm wide and 124.06mm tall with 99.mm separation between 
the two syringe connectors (see Figure 1a). The mixing portion included 15 rotations 
within 29.30mm to insure a homogenous solution (see Figure 1b). The separation and 
height were too large for practical use; the syringes were too far apart to simultaneously 
inject into the device (see Figure 1c).  
 
Figure 1a. This figure is the front 
view of prototype one. The 
syringes connect to the top and 
the needle connects to the 
bottom. 
Figure 1b. This figure is the 
translucent front view of 
prototype one. The mixing 
portion of the syringe contained 
15 rotations in 29.30mm. 
Figure 1c. This figure is the 
trimetric view of prototype one. 
The syringes were too far apart 
and the device was too tall. 
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3.1.2 Prototype Two. A more practical design was created for the second prototype (see 
Figure 2a). This design was much smaller at 40.66mm wide, 46.00mm tall, and 9.23mm 
separation between the syringe connectors. The thickness of the walls was 3.00mm while 
the syringe connector diameter was 16.00mm. The previous mixing component included 
in the first prototype was eliminated because the fluid dynamics of the small tube would 
cause natural mixing. Although the second prototype featured a more ergonomic design, 
the connectors were too large to secure the syringes and needle. The thickness of the 
device walls also needed modifications (see Figure 2c). 
 
3.1.3 Prototype Three. The ergonomic separation of connectors and height of the device 
were established in the second prototype and used throughout the rest of the prototypes; 
all future prototypes also eliminated the mixing component (see Figure 3b). The third 
prototype reduced the wall thickness to 0.40mm and connector diameter to 4.20mm (see 
Figure 2a. This figure is the front 
view of prototype two. The 
connectors for the syringes and 
the needle were too large. 
Figure 2b. This figure is the 
translucent trimetric view of 
prototype two. There is no 
mixing system: enough mixing 
will occur in the needle. 
Figure 2c. This figure is the 
trimetric view of prototype two. 
The thickness of device walls 
needs to be decreased. 
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Figure 3a). This design also failed to connect properly to the syringes and needle; the 
connectors for this prototype were too small (see Figure 3c). 
 
3.1.4 Prototype Four. The fourth prototype kept the same wall thickness but increased 
the connector diameter to 8.10mm (see Figure 4c). The geometry of the needle connector 
changed from an angular connector to a vertical connector (see Figure 4b); this change 
relieved SolidWorks design difficulties associated with the angular geometry. Two 
different syringe connectors were designed to test the assembly of the syringe and the 
device (see Figure 4c). The needle locked into the connector and the syringe locked into 
the right connector; this connector had an additional angular piece to help secure the 
locking mechanism. The left connector was straight making the syringe screw into the 
connector continuously thus interfering with the syringe locking into the device (see 
Figure 4a). 
Figure 3a. This figure is the front 
view of prototype three. The 
connectors for the syringes and 
the needle were too small. 
Figure 3b. This figure is the 
translucent front view of 
prototype three. The small 
opening causes enough mixing. 
Figure 3c. This figure is the 
trimetric view of prototype three. 
The device wall thickness was 
fixed from the previous 
prototype. 
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3.2 Reinforcing the Needle Connector 
3.2.1 Prototype Five. The fifth prototype was the same as the fourth design, but both 
syringe connectors resembled the right (angular) connector (see Figure 5a). After 
multiple demonstrations of the connectors and a fluid dynamic study with distilled water, 
the inside needle connector component broke. The thickness of the inside wall was weak 
at the interface of the two channels to one channel (see Figure 5b).  
Figure 4a. This figure is the front 
view of prototype four. The right 
connectors for the syringes and 
the needle fit best. 
Figure 4b. This figure is the 
translucent front view of 
prototype four. The needle 
connector changed from angular 
to straight. 
Figure 3c. This figure is the 
trimetric view of prototype four. 
To decrease prototype iterations, 
two different connector shapes 
were printed. 
Figure 5a. This figure is the 
front view of prototype five. 
The syringe connectors are 
the same as the right syringe 
connector in prototype four. 
Figure 5b. This figure is the 
translucent front view of 
prototype five. The clear part 
represents the wall thickness. 
The arrow points to the 
limited wall thickness.  
 12 
 
3.2.2 Prototype Six. The thickness of the inside needle connector could not simply be 
increased without creating a completely new design. By making the two channels connect 
more quickly, the thickness of the inside connector was increased (See Figure 6). The 
increase was enough to last through multiple fluid dynamic tests with distilled water. The 
instant forming hydrogel was tested using the device. With pressure from the table, the 
solutions were mixed enough to form the hydrogel. After a few uses, again the inside 
needle connector broke. Instead of changing the device dimensions, the following 
prototypes tested the strength using different printing materials. 
 
3.3 Material Testing 
3.3.1 Prototype Seven. The first six prototypes were printed on an Object30 printer using 
VeroWhite material (similar to polypropylene (PP)). The dimensional limit of the printer 
is 0.1mm. In an attempt to reduce printing costs, the MakerBot Replicator 2X (from now 
on referred to as the MakerBot) printer was used; this printer uses polylactide (PLA). 
Figure 6. This figure is the 
front view of prototype six. 
The clear part represents the 
wall thickness. The arrow 
points to the increased wall 
thickness.  
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With a dimensional limit of 0.8mm, the seventh prototype was unusable because the 
device was not properly printed (see Figure 7). 
 
3.3.2 Prototype Eight. Because the sixth prototype was not strong enough for multiple 
uses, a stronger material was needed. For preclinical uses, a multiple-use device must be 
easily sterilized. VeroWhite cannot be sterilized by either ethylene-oxide or autoclaved, 
both available in the lab. Acrylonitrile butadiene styrene (ABS) can be sterilized by 
ethylene-oxide. An uPrint SE Plus printer was used to create the ABS prototype. Along 
with its sterility, the prototype was considerably stronger allowing many uses before 
failure (see Figure 8). The prototype was rougher than the VeroWhite prototype. The 
increased roughness led to increased pressure; the solutions no longer mixed into a single 
channel but overflowed at the site of the syringe connector. 
Figure 7. This figure is a 
photo of prototype seven. 
The dimensional limit of the 
MakerBot was not small 
enough causing inaccurate 
printing.  
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4. Discussion 
4.1 Fitting the Syringes and Needle. Except for the first prototype, the first four 
prototypes were iterations of differing connector diameter and wall thickness. The device 
was created for easy use in a laboratory setting and eventually a clinical setting; therefore 
the ergonomics of the device was a high priority. The trouble with connector fitting was 
an issue with measurements. With no prior SolidWorks experience, I learned how to use 
the software through trial and error. For the first prototype, my dimensions were not 
easily visualized causing a large and hardly usable device. The second and third 
prototype dimensional incorrectness arose from measuring errors of the needle and 
syringe and mistakes in distinguishing the radius and diameter of the connectors.  
By the fourth prototype, I had hours of exposure to SolidWorks keeping me from making 
novice mistakes. After using a caliber to measure the syringe and needle and confidence 
in my design ability, I chose to decrease the prototype iterations by utilizing the two 
Figure 8. This figure is a 
photo of prototype eight. The 
uPrint SE Plus printer created 
a prototype made of ABS. 
The material was too rough 
and caused overflowing of 
the hydrogel mixture. 
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syringe connectors. There were two proposed designs for this connector. Designing the 
connectors with the two different designs allowed for increased feedback because 
multiple prototypes did not need printing. The angled connector gave more support and 
was more appealing; the straight design on the other connector was simpler. The straight 
design was strong enough, but it made the syringe continuously screw onto the connector. 
This continuous screwing decreased stability. The angled connector increased the 
stability of the syringe device connection because a locking affect occurred between the 
female and male connector. Because proper fitting was not established for both syringes 
and the needle, no fluid dynamic studies ensued. 
4.2 Reinforcing the Needle Connector. At the time, I thought the fifth prototype would 
be the last iteration. All parts were able to connect, and the first fluid dynamics test with 
distilled water was successful. The water was able to flow from both syringes out of the 
needle. After multiple tries, the inside needle connector broke. The SolidWorks drawing 
gave insight to the broken connector; the wall at the interface to one connector was 
meager. The inside connector thickness was critical for the needle connection; an 
innovative modification was needed to add strength without directly changing the 
thickness. By decreasing the distance to combine the syringe channels into one channel, 
thickness was indirectly added to the interface. 
The sixth prototype used this design modification. The fluid dynamics were tested again 
with distilled water. With successful testing, the two components needed to create the 
instant forming hydrogel were tested. When pressure from the table was applied to the 
needle opening, the hydrogel formed as it came out of the needle tip. After a few more 
uses of the device, it broke again. With successful creation of the hydrogel from the 
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device, printing materials became the focus of strengthening the device and making the 
device sterile. 
4.3 Material Testing. The first six prototypes were printed with VeroWhite on an 
Object30 printer. Accessibility of the printer was the main reason the first prototypes 
were printed using the Object30. Once the material of the prototype became a factor, 
different printers were explored. 
The MakerBot printer used PLA, a more cost effective material. This printer was also 
easily accessible. One concern was the decreased dimensional limit of the printer. 
Because the prototype was small and precise, the dimensional limit of the printer needed 
to be on the order of a tenth of a millimeter. The seventh prototype was created using the 
MakerBot and was unusable. Without even trying to connect the syringe or needle, it was 
obvious the device could not be utilized. 
After investigating different materials, ABS was an accessible material with greater 
strength and the ability to be sterilized with ethylene-oxide. The first time the prototype 
was printed one of the connectors was filled with ABS. After changing the printer 
orientation from vertical to horizontal, both connectors were printed hollow. The 
promising strength and sterility of the material became useless after testing the hydrogel 
solutions. Both solutions overflowed from the syringe connection. We assumed the 
increased roughness of the ABS prototype caused the overflow. ABS was not an ideal 
material for this device. 
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5. Conclusion 
This study proposed creating a new medical device for the use of an injectable instant 
forming hydrogel. Through this investigation, the dimensions of a mixing device for two 
solutions into one mixture with immediate injection abilities were created. In the process, 
eight prototypes were created. Six of the prototypes were concerned with the dimensions 
of the device while the other two focused on the materials of the device. 
For multiple uses, the device needs sterility capabilities. With the hydrogel forming 
instantly, some hydrogel would form in the device. The sterilizing process would clean 
the device of any leftover materials and keep disease from spreading. The roughness of 
ABS was found to be cause problems with mixing. Another material is needed for the 
device to be used. 
Further studies could be conducted to determine a material suitable for the device and the 
feasibility of mass-producing the device. While determining the feasibility, the market 
value of the device could be determined. To increase the impact of the device, further 
research could determine other applications of the mixing device in medicine. 
Dimensional experimenting could lead to an optimal length of existing parts for hydrogel 
formation. Because changes in the two solutions impact the hydrogel formation time, the 
device could test the characteristics of different formulation times. 
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